Publications
34
Citations
1,032
Est. group size
—
Recurring co-author estimate
Active years
29
Publishing since 1998
B.H. Rovin's research focuses on kidney diseases caused by immune system dysfunction, particularly lupus nephritis (kidney inflammation from lupus) and IgA nephropathy (a kidney disease involving abnormal antibody deposits). Much of the work involves testing new drugs, such as B-cell depleting therapies (obinutuzumab, belimumab) and other immune-targeting treatments, through large clinical trials, and identifying biomarkers to track kidney disease progression. This research is relevant to students interested in clinical nephrology, immunology, and translational drug trials for autoimmune kidney conditions.
Publication activity was minimal in the middle of the decade but has increased sharply in the last two years, with output rising from occasional single papers to multiple publications in 2025 and 2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Complement inhibitors and B cell–modifying agents for IgA nephropathy—a Kidney Disease: Improving Global Outcomes (KDIGO) commentary
Kidney International · 2026
- WCN26-8365 DURATION OF ABSOLUTE PROTEINURIA RESPONSE WITH NEFECON IN PATEINTS WITH PRIMARY IMMUNOGLOBULILN A NEPHROPATHY: RESULTS FROM THE 2-YEAR NEFIGARD TRIAL
Kidney International Reports · 2026
- WCN26-8170 Urine protein–creatinine ratio response at 12 months in patients with immunoglobulin A nephropathy receiving nefecon vs placebo: Analysis of NefIgArd trial data
Kidney International Reports · 2026
- WCN26-5435 CD93 IS A NOVEL ENDOTHELIAL PREDICTIVE AND THERAPEUTIC TARGET IN NEPHROTIC SYNDROME
Kidney International Reports · 2026
- WCN26-8313 ABSOLUTE PROTEINURIA OVER TIME WITH NEFECON VS PLACEBO IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY: RESULTS FROM THE PHASE 3 NEFIGARD TRIAL
Kidney International Reports · 2026
- WCN26-3469 OBINUTUZUMAB INDUCES HISTOLOGIC REMISSION AND DEEP KIDNEY PARENCHYMAL B-CELL DEPLETION IN PATIENTS WITH LUPUS NEPHRITIS: EXPLORATORY ANALYSES FROM THE REGENCY TRIAL
Kidney International Reports · 2026
- POS0966 OBINUTUZUMAB SHOWS PROMISE IN LUPUS NEPHRITIS REGARDLESS OF BASELINE SEROLOGICAL BIOMARKERS: AN EXPLORATORY POST HOC ANALYSIS OF THE PHASE II NOBILITY STUDY
Annals of the Rheumatic Diseases · 2025
- L’obinutuzumab prometteur dans la néphrite lupique indépendamment des biomarqueurs sérologiques initiaux : analyse exploratoire post hoc de l’étude de phase II NOBILITY
Revue du Rhumatisme · 2025
- Effets pharmacodynamiques de l’obinutuzumab sur les lymphocytes B et les marqueurs sérologiques chez des patients atteints de néphrite lupique active : résultats de l’étude de phase III REGENCY
Revue du Rhumatisme · 2025
- L’obinutuzumab démontre un bénéfice constant avec de nombreuses définitions du critère d’évaluation principal d’après les résultats de l’étude REGENCY chez des patients atteints de néphrite lupique active
Revue du Rhumatisme · 2025
- POS0739 RENIN-ANGIOTENSIN SYSTEM BLOCKADE SIGNIFICANTLY REDUCES FUTURE CARDIOVASCULAR RISK IN LUPUS NEPHRITIS
Annals of the Rheumatic Diseases · 2024
- POS0690 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
Annals of the Rheumatic Diseases · 2021
- Effets du belimumab sur la fonction rénale, le contrôle global et les biomarqueurs du lupus systémique
La Revue de Médecine Interne · 2021
- Tolérance et efficacité du belimumab intraveineux dans une étude d’extension en ouvert de 6 mois chez des patients atteints de glomérulonéphrite lupique
La Revue de Médecine Interne · 2021
- SUN-374 B-CELL DEPLETION AND RESPONSE IN A RANDOMIZED, CONTROLLED TRIAL OF OBINUTUZUMAB FOR PROLIFERATIVE LUPUS NEPHRITIS
Kidney International Reports · 2020
- Kidney International Reports×7
- Annals of the Rheumatic Diseases×3
- Revue du Rhumatisme×3
- La Revue de Médecine Interne×2
- Lupus×1
- Jessica Greco
Medicine · The Ohio State University
- Huijuan Song
Medicine · The Ohio State University
- Stacy P. Ardoin
Medicine · The Ohio State University
- Brad H. Rovin
Medicine · The Ohio State University
- Haichang Li
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile